Advertisement

PharmacoEconomics Italian Research Articles

, Volume 1, Issue 1, pp 35–41 | Cite as

HAART (zidovudina, lamivudina, indinavir): analisi dei costi in una popolazione di pazienti HIV positivi con conta linfocitaria CD4+ < 200/mmc

  • Raffaele Bruno
  • P. Sacchi
  • S. F. A. Patruno
  • U. di Luzio Paparatti
  • M. Font
  • P. Piacentini
  • F. Zara
  • P. Legnazzi
  • G. Filice
Article

Summary

Objective To analyze the cost of a population of HIV patients with less than 200 CD4 cell count treated with HAART (highly active antiretroviral therapy).

Design Retrospective study

Setting IRCCS Policlinico S. Matteo Pavia, Italy, University of Pavia, Italy.

Patients and participants 181 HIV positive patients with less than 200 CD4 cell count observed from January 1996 until December 1997.

Main outcome measures Hospitalization, days of stay, AIDS definig events, deaths, direct cost, assessed during two years follow-up.

Results During follow-up hospitalizations decreased from 154 to 118, while hospital stays dropped from 3429 to 2832 days, with the decrease beginning at the start of the 2nd four-month period of 1997. There was a reduction in terms of time of AIDS defining events (ADE) compared to those of 1996; in 1997 there was a 70% decrease in new diagnoses. Likewise, for deaths, there was a constant decrease in 1997 when compared to 1996 where there was a peak in the third four-month period. Total costs of our patient cohort were similar for 1996 and 1997, with a shift occurring from hospitalization costs to anti-retroviral therapy costs.

Conclusion Our data indicate that patients with CD4 < 200/mmc, that is that population carrying the greatest health costs, does not result in relevant added costs when HAART is used (plus 10% on pro-capite for year bases) but, rather, creates a shift from one type of cost to another.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Bibliografia

  1. 1.
    Hammer SM, Squires EK, Hughes MD, et al. A controlled trial of two nucleoside analogues plus Indivanir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl Med 1997; 337, 725–733CrossRefGoogle Scholar
  2. 2.
    Kennelly JM, Tolley KH, Ghani ACH, et al. Hospital costs of treating haemophiliac patients infected with HIV. AIDS 1995; 9, 787–193PubMedCrossRefGoogle Scholar
  3. 3.
    Cunnigham D, Griffiths SF. AIDS: counting the cost. BMJ 1987; 295, 921–922CrossRefGoogle Scholar
  4. 4.
    Beck EJ, Kennelly J, McKevitt C, et al. Changing use of hospital services and costs at a London referral service 1983–1989. AIDS 1991; 8, 367–377CrossRefGoogle Scholar
  5. 5.
    Moore RD, Chaisson RE. Cost to Medicaid of advancing Immunosuppression in an urban HIV-infected patient population in Maryland. JAIDS 1997; 14, 223–231PubMedGoogle Scholar
  6. 6.
    Mouton Y, Alfandari S, Valette M, et al. Impact of protease inhibitor on AIDS-defining events and hospitalizations in 10 French AIDS reference centres. AIDS 1997; 11, F101–F105PubMedCrossRefGoogle Scholar
  7. 7.
    Bennett CL, Pascal A, Cvitanic M, et al. Medical care cost of intravenous drug users with AIDS in Brooklin. JAIDS 1992; 5. 1–6Google Scholar
  8. 8.
    Beck EJ, Kennelly J, McKevitt C, et al. Changing presentation and survival, service utilization and costs for AIDS patients: insights from a London referral centre. AIDS 1994; 8, 379 384PubMedGoogle Scholar
  9. 9.
    Moore RD, Bartlett JG. Combination antiretroviral therapy in HIV infection. An economic perspsective. Pharmacoeconomics 1996; 10(2), 109–113PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 1999

Authors and Affiliations

  • Raffaele Bruno
    • 1
  • P. Sacchi
    • 1
  • S. F. A. Patruno
    • 1
  • U. di Luzio Paparatti
    • 1
  • M. Font
    • 1
  • P. Piacentini
    • 2
  • F. Zara
    • 1
  • P. Legnazzi
    • 2
  • G. Filice
    • 1
  1. 1.Divisione di Malattie Infettive e Tropicali IRCCS, Policlinico S. Matteo PaviaUniversità degli Studi di PaviaItalia
  2. 2.Dipartimento di Farmacologia IRCCSPoliclinico S. Matteo PaviaItalia

Personalised recommendations